Phenyramidol

Phenyramidol

SCHEMBL13310227

O[C@H](CNc1ccccn1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 1.00
KDM4E B2RXH2 3/20 0.58
FDPS P14324 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.53
FABP1 P07148 1/20 0.51
FABP6 P51161 1/20 0.51
FAAH O00519 10/20 0.50
AOC3 Q16853 3/20 0.50
CXCR4 P61073 1/20 0.49
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenyramidol SCHEMBL13310219 1.00 CYP2D6 (1.00) CYP2D6KDM4EFDPSL3MBTL1FABP1
Phenyramidol SCHEMBL29500950 1.00 CYP2D6 (1.00) CYP2D6KDM4EFDPSL3MBTL1FABP1
Phenyramidol SCHEMBL21963 1.00 CYP2D6 (1.00) CYP2D6KDM4EFDPSL3MBTL1FABP1
Phenyramidol SCHEMBL20769334 0.98 CYP2D6 (0.97) CYP2D6KDM4EFDPSL3MBTL1FABP1
Phenyramidol SCHEMBL29375712 0.98 CYP2D6 (0.97) CYP2D6KDM4EFDPSL3MBTL1FABP1
Phenyramidol SCHEMBL121004 0.98 CYP2D6 (0.97) CYP2D6KDM4EFDPSL3MBTL1FABP1
Phenyramidol SCHEMBL3446649 0.94 CYP2D6 (0.88) CYP2D6KDM4EFDPSL3MBTL1FABP1
SCHEMBL9566716 0.87 CYP2D6 (0.77) CYP2D6KDM4EFDPSFABP1FABP6
Phenyramidol SCHEMBL22718457 0.84 CYP2D6 (0.71) CYP2D6KDM4EFDPSFAAHAOC3
SCHEMBL4281005 0.84 CYP2D6 (0.72) CYP2D6KDM4EFDPSL3MBTL1FABP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130143932-A1 OPTICAL ENANTIOMERS OF PHENYRAMIDOL AND PROCESS FOR CHIRAL SYNTHESIS FERMENTA BIOTECH (UK) LIMITED (GB) 2013-06-06 US disclosed
US-20130143932-A1 OPTICAL ENANTIOMERS OF PHENYRAMIDOL AND PROCESS FOR CHIRAL SYNTHESIS FERMENTA BIOTECH (UK) LIMITED (GB) 2013-06-06 US disclosed
US-8389551-B2 Optical enantiomers of phenyramidol and process for chiral synthesis FERMENTA BIOTECH (UK) LIMITED (GB) 2013-03-05 US disclosed
US-8389551-B2 Optical enantiomers of phenyramidol and process for chiral synthesis FERMENTA BIOTECH (UK) LIMITED (GB) 2013-03-05 US disclosed
US-20100144799-A1 OPTICAL ENANTIOMERS OF PHENYRAMIDOL AND PROCESS FOR CHIRAL SYNTHESIS FERMENTA BIOTECH (UK) LIMITED (GB) 2010-06-10 US disclosed
US-20100144799-A1 OPTICAL ENANTIOMERS OF PHENYRAMIDOL AND PROCESS FOR CHIRAL SYNTHESIS FERMENTA BIOTECH (UK) LIMITED (GB) 2010-06-10 US disclosed
US-20090182016-A1 OPTICAL ENANTIOMERS OF PHENYRAMIDOL AND PROCESS FOR CHIRAL SYNTHESIS FERMENTA BIOTECH (UK) LIMITED (GB) 2009-07-16 US disclosed
US-20090182016-A1 OPTICAL ENANTIOMERS OF PHENYRAMIDOL AND PROCESS FOR CHIRAL SYNTHESIS FERMENTA BIOTECH (UK) LIMITED (GB) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182016-A1 OPTICAL ENANTIOMERS OF PHENYRAMIDOL AND PROCESS FOR CHIRAL SYNTHESIS QDPR, DYRK4, DYRK3 CYP2D6 5/4885KDM4E 3870/4885FDPS 401/4885
US-20100144799-A1 OPTICAL ENANTIOMERS OF PHENYRAMIDOL AND PROCESS FOR CHIRAL SYNTHESIS QDPR, CYP3A4, PPOX CYP2D6 4/4885KDM4E 3510/4885FDPS 401/4885
US-20130143932-A1 OPTICAL ENANTIOMERS OF PHENYRAMIDOL AND PROCESS FOR CHIRAL SYNTHESIS QDPR, CYP3A4, PPOX CYP2D6 4/4885KDM4E 3510/4885FDPS 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.